About: Daridorexant

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action.

Property Value
dbo:abstract
  • Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben. (de)
  • Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. Daridorexant was approved for medical use in the United States in January 2022 and became available in May 2022. It was approved in the European Union in April 2022, and is the first orexin receptor antagonist to become available in European Union. The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse. (en)
  • Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022). (ru)
dbo:alternativeName
  • Quviviq (en)
dbo:bioavailability
  • 62.000000 (xsd:float)
dbo:casNumber
  • 1505484-82-1
  • 1792993-84-0
dbo:chEMBL
  • 4297590
  • 4650216
dbo:class
dbo:drugbank
  • DB15031
dbo:fdaUniiCode
  • 9X9581N56R
  • LMQ24G57E9
dbo:kegg
  • D11886
  • D11887
dbo:pubchem
  • 91801202
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 57716248 (xsd:integer)
dbo:wikiPageLength
  • 39081 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1124842465 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:bioavailability
  • 62.0
dbp:c
  • 23 (xsd:integer)
dbp:casNumber
  • 1505484 (xsd:integer)
  • 1792993 (xsd:integer)
dbp:chembl
  • 4297590 (xsd:integer)
  • 4650216 (xsd:integer)
dbp:chemspiderid
  • 64854514 (xsd:integer)
dbp:cl
  • 1 (xsd:integer)
dbp:class
dbp:dailymedid
  • Daridorexant (en)
dbp:drugbank
  • DB15031 (en)
dbp:durationOfAction
  • 28800.0
dbp:eliminationHalfLife
  • 28800.0
dbp:excretion
  • Feces: ~57% (en)
  • Urine: ~28% (en)
dbp:h
  • 23 (xsd:integer)
dbp:index2Label
  • as HCl (en)
dbp:iupacName
  • [-2--2-methylpyrrolidin-1-yl]-[5-methoxy-2-phenyl]methanone (en)
dbp:iupharLigand
  • 11648 (xsd:integer)
dbp:kegg
  • D11886 (en)
  • D11887 (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Schedule IV (en)
dbp:metabolism
  • Extensive (en)
dbp:n
  • 6 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:onset
  • -7200.0
dbp:pdbLigand
  • NS2 (en)
dbp:proteinBound
  • 99.7
dbp:pubchem
  • 91801202 (xsd:integer)
  • 91809208 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • CC1=CCl (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NBGABHGMJVIVBW-QHCPKHFHSA-N (en)
dbp:synonyms
  • Nemorexant; ACT-541468 (en)
dbp:tradename
  • Quviviq (en)
dbp:unii
  • 9 (xsd:integer)
  • LMQ24G57E9 (en)
dbp:usan
  • Daridorexant hydrochloride (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Daridorexant ist ein Arzneistoff aus der Gruppe der Orexinrezeptor-Antagonisten. Er wurde in den USA im Januar 2022 und in der EU im April 2022 unter dem Namen Quviviq zur Behandlung von Schlafstörungen zugelassen. Das Mittel wird oral gegeben. (de)
  • Даридорексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2022). (ru)
  • Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth. Side effects of daridorexant include headache, somnolence, and fatigue. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. (en)
rdfs:label
  • Daridorexant (en)
  • Daridorexant (de)
  • Даридорексант (ru)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:product of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:products of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License